TABLE 1.
Main clinical findings in the phase II dose-finding study of ganirelix.
| Daily dose of ganirelix (mg) |
||||||
|---|---|---|---|---|---|---|
| 0.0625 (n = 31) | 0.125 (n = 65) | 0.25 (n = 69) | 0.5 (n = 69) | 1.0 (n = 65) | 2.0 (n = 30) | |
| Serum LH rise of ≥10 IU/L during ganirelix treatment | 5 | 6 | 1 | - | - | - |
| Serum LH (IU/L) on the day of hCG treatment | 3.6 | 2.5 | 1.7 | 1.0 | 0.6 | 0.4 |
| Serum estradiol (pg/mL) on the day of hCG treatment | 1475 | 1130 | 1160 | 823 | 703 | 430 |
| Oocytes | 9.0 | 9.5 | 10.0 | 8.8 | 9.3 | 8.6 |
| Good-quality embryos (day 3) | 3.8 | 3.3 | 3.3 | 2.5 | 3.3 | 3.5 |
| Implantation rate (%) | 14.2 | 16.6 | 21.9 | 9.0 | 8.8 | 1.5 |
| Ongoing pregnancy rate (%) per started stimulation | 23.3 | 23.1 | 33.8 | 10.1 | 14.1 | 0 |
| Ongoing pregnancy rate (%) per transfer | 25.9 | 25.0 | 37.1 | 13.0 | 15.3 | 0 |
Note: hCG = human chorionic gonadotropin; LH = luteinizing hormone.